BR9405404A - Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação - Google Patents

Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação

Info

Publication number
BR9405404A
BR9405404A BR9405404A BR9405404A BR9405404A BR 9405404 A BR9405404 A BR 9405404A BR 9405404 A BR9405404 A BR 9405404A BR 9405404 A BR9405404 A BR 9405404A BR 9405404 A BR9405404 A BR 9405404A
Authority
BR
Brazil
Prior art keywords
pct
terpene compounds
compounds
arachidonic acid
sec
Prior art date
Application number
BR9405404A
Other languages
English (en)
Inventor
Uwe R Juergens
Original Assignee
Uwe R Juergens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de
Priority claimed from DE4319554A external-priority patent/DE4319554C2/de
Application filed by Uwe R Juergens filed Critical Uwe R Juergens
Publication of BR9405404A publication Critical patent/BR9405404A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9405404A 1993-06-13 1994-06-11 Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação BR9405404A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19934319556 DE4319556C2 (de) 1993-06-13 1993-06-13 Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
DE4319554A DE4319554C2 (de) 1993-06-13 1993-06-13 Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (de) 1993-06-13 1994-06-11 Verwendung von terpenverbindungen zur verminderten freisetzung von arachidonsäure und entzündungsmediatoren

Publications (1)

Publication Number Publication Date
BR9405404A true BR9405404A (pt) 1999-05-25

Family

ID=25926728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9405404A BR9405404A (pt) 1993-06-13 1994-06-11 Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação

Country Status (19)

Country Link
US (1) US5889049A (pt)
EP (1) EP0654994B1 (pt)
JP (1) JPH08500612A (pt)
AT (1) ATE173622T1 (pt)
AU (1) AU680663B2 (pt)
BG (1) BG62474B1 (pt)
BR (1) BR9405404A (pt)
CA (1) CA2140660A1 (pt)
CZ (1) CZ285025B6 (pt)
DE (1) DE59407336D1 (pt)
DK (1) DK0654994T3 (pt)
ES (1) ES2126123T3 (pt)
HU (1) HUT69684A (pt)
NO (1) NO313814B1 (pt)
PL (1) PL308539A1 (pt)
RO (1) RO111989B1 (pt)
RU (1) RU2161482C2 (pt)
SK (1) SK282308B6 (pt)
WO (1) WO1994028895A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
GB2329583A (en) * 1997-09-25 1999-03-31 Marilyn Rydstrom Use of tea-tree oil for prophylaxis against cystitis
DE69934681T2 (de) 1998-04-16 2007-11-08 Eurovita A/S Neue synergistische zusammensetzungen, die aromatische verbindungen und in alpinia galanga vorhandene terpenoide enthalten
US6420435B1 (en) 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6733794B1 (en) * 1999-12-17 2004-05-11 Edward L. Ingram Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
DE102009037359A1 (de) 2008-09-04 2010-06-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpene für die Behandlung von Atemwegserkrankungen, insbesondere von bronchopulmonalen Erkrankungen
DE202010007074U1 (de) 2010-05-12 2011-08-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
DE102010022174A1 (de) 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
CA2814431A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
AU2012214553B2 (en) * 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
DE202012000910U1 (de) 2012-01-20 2013-01-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) * 2012-03-12 2012-07-12 Lotte Co Ltd 線毛運動活性化剤及びそれを含む飲食品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
JP2524709B2 (ja) * 1985-09-26 1996-08-14 塩野義製薬株式会社 鎮痛消炎作用増強剤
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
WO1991013627A1 (en) * 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
JPH0426619A (ja) * 1990-05-18 1992-01-29 Lotte Co Ltd 抗アレルギー剤および抗アレルギー剤を含有する食品添加物
AU1783092A (en) * 1991-04-08 1992-11-02 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Inhibitors of protein kinase c function
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US5338758A (en) * 1992-04-03 1994-08-16 Schering Corporation Bicyclic diterpene PAF antagonist compounds
DE4211745A1 (de) * 1992-04-03 1993-10-07 Boerner Gmbh Verwendung von Propolis und/oder seinen Fraktionen
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Also Published As

Publication number Publication date
AU680663B2 (en) 1997-08-07
WO1994028895A3 (de) 1995-04-06
SK282308B6 (sk) 2002-01-07
US5889049A (en) 1999-03-30
RU2161482C2 (ru) 2001-01-10
ES2126123T3 (es) 1999-03-16
CZ37095A3 (en) 1995-11-15
AU7000394A (en) 1995-01-03
NO950518L (no) 1995-02-10
ATE173622T1 (de) 1998-12-15
JPH08500612A (ja) 1996-01-23
PL308539A1 (en) 1995-08-21
BG99499A (bg) 1995-12-29
BG62474B1 (bg) 1999-12-30
HUT69684A (en) 1995-09-28
RO111989B1 (ro) 1997-04-30
CZ285025B6 (cs) 1999-05-12
EP0654994B1 (de) 1998-11-25
CA2140660A1 (en) 1994-12-22
HU9500714D0 (en) 1995-04-28
NO313814B1 (no) 2002-12-09
DE59407336D1 (de) 1999-01-07
EP0654994A1 (de) 1995-05-31
WO1994028895A2 (de) 1994-12-22
DK0654994T3 (da) 1999-08-09
SK30395A3 (en) 1995-11-08
NO950518D0 (no) 1995-02-10

Similar Documents

Publication Publication Date Title
BR9405404A (pt) Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
AU5876596A (en) Oral dosage and method for treating painful conditions of th e oral cavity
MX9703354A (es) Composiciones para tratar el acné y curar heridas que contienen un piruvato, un antioxidante y una mezcla de acidos grasos.
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
EP1093816A3 (en) Use of ST1435 in hormonal therapy by transdermal application
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
KR910005858A (ko) 지방산 요법
ATE162719T1 (de) Ophthalmische zubereitung
GR3022074T3 (en) Method for treatment or prevention of obesity.
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
AU4132397A (en) Therapeutic formulations containing venom or venom anti-serum either lone or in combination for the therapeutic prophylaxis and therapy of neoplasms
Van der Rhee et al. Treatment of psoriasis vulgaris with a low-dosage Ro 10-9359 (Tigason) orally combined with corticosteroids topically
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
WO2001001995A3 (en) Method for treatment of asthma syndrome
RU2043104C1 (ru) Болеутоляющее средство при хроническом панкреатите
Regan et al. The effects of Ro15-1788, alone and in combination with diazepam, on ethanol-induced loss of righting reflex in rats
Gould et al. Porcine dermis dressings in epidermolysis bullosa
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
Schettino et al. A mild form of captopril-induced pemphigus

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/045 (2006.01), A61K 31/35 (2006.0